Interestingly, ATM deficiency predicted PARP1 inhibitor sensitivity in p53-null gastric cancer cells, and it was speculated that combined inhibition of ATM and PARP1 is a potential therapy for p53-disrupted gastric cancer [47]. The gene discussed is PARP1; the disease is gastric cancer.